retatrutide clinical trials netherlands Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced Designing Next-Generation Cardiometabolic Outcome Trials
Description
But breakfast has taken a hit, particularly from high-income GLP-1 users, who represent a bigger percentage of current patients, she said
By activating GLP-1, GIP, and glucagon receptors, it could increase overall calorie burning, improve how sugars and fats are processed after meals, support steadier blood glucose levels, and gradually reduce fat mass
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials
And you want to be long biotech
